These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 22590681)

  • 1. Structural basis for differential neutralization of ebolaviruses.
    Bale S; Dias JM; Fusco ML; Hashiguchi T; Wong AC; Liu T; Keuhne AI; Li S; Woods VL; Chandran K; Dye JM; Saphire EO
    Viruses; 2012 Apr; 4(4):447-70. PubMed ID: 22590681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A shared structural solution for neutralizing ebolaviruses.
    Dias JM; Kuehne AI; Abelson DM; Bale S; Wong AC; Halfmann P; Muhammad MA; Fusco ML; Zak SE; Kang E; Kawaoka Y; Chandran K; Dye JM; Saphire EO
    Nat Struct Mol Biol; 2011 Nov; 18(12):1424-7. PubMed ID: 22101933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
    Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
    ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.
    Bornholdt ZA; Ndungo E; Fusco ML; Bale S; Flyak AI; Crowe JE; Chandran K; Saphire EO
    mBio; 2016 Feb; 7(1):e02154-15. PubMed ID: 26908579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
    Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
    J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
    Shedlock DJ; Bailey MA; Popernack PM; Cunningham JM; Burton DR; Sullivan NJ
    Virology; 2010 Jun; 401(2):228-35. PubMed ID: 20304456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
    Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.
    Lee JE; Saphire EO
    Curr Opin Struct Biol; 2009 Aug; 19(4):408-17. PubMed ID: 19559599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
    Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
    Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of broad ebolavirus neutralization by a human survivor antibody.
    West BR; Wec AZ; Moyer CL; Fusco ML; Ilinykh PA; Huang K; Wirchnianski AS; James RM; Herbert AS; Hui S; Goodwin E; Howell KA; Kailasan S; Aman MJ; Walker LM; Dye JM; Bukreyev A; Chandran K; Saphire EO
    Nat Struct Mol Biol; 2019 Mar; 26(3):204-212. PubMed ID: 30833785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
    Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
    Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop.
    Janus BM; van Dyk N; Zhao X; Howell KA; Soto C; Aman MJ; Li Y; Fuerst TR; Ofek G
    Nat Commun; 2018 Sep; 9(1):3934. PubMed ID: 30258051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.
    Frei JC; Nyakatura EK; Zak SE; Bakken RR; Chandran K; Dye JM; Lai JR
    Sci Rep; 2016 Jan; 6():19193. PubMed ID: 26758505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.